Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
According to the recently published report 'Aryl Hydrocarbon Receptor - Drugs In Development, 2022'; Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 32 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes.
Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Aryl hydrocarbon receptor is a protein encoded by the AHR gene. It mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. It involved in cell-cycle regulation. It plays an important role in the development and maturation of many tissues. It regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1.
The report 'Aryl Hydrocarbon Receptor - Drugs In Development, 2022' outlays comprehensive information on the Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 4, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Gastrointestinal, Dermatology, Central Nervous System, Infectious Disease, Metabolic Disorders, Ophthalmology and Respiratory which include indications Coronavirus Disease 2019 (COVID-19), Psoriasis, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Atopic Dermatitis (Atopic Eczema), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Inflammatory Bowel Disease, Multiple Sclerosis, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes), Ulcerative Colitis, Unspecified Cancer, Unspecified Dermatological Disorders, Uveitis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Respiratory Distress Syndrome, Alopecia, Androgen-Sensitive Prostate Cancer, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Blepharitis, Burkitt Lymphoma, Celiac Disease, Colitis, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Crohn's Disease (Regional Enteritis), Dengue Fever, Graft Versus Host Disease (GVHD), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Keratoconjunctivitis Sicca (Dry Eye), Lupus Nephritis, Mantle Cell Lymphoma, Melanoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Myasthenia Gravis, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Oral Cancer, Osteoarthritis Pain, Pancreatic Ductal Adenocarcinoma, Pemphigus, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), T-Cell Lymphomas, Transitional Cell Cancer (Urothelial Cell Cancer), Vitiligo, Wet (Neovascular / Exudative) Macular Degeneration and Zika Virus Infections.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook